Takeda’s Iclusig Looks Set To Become SOC In First-Line Ph+ Acute Lymphoblastic Leukemia

 
• By Alaric DeArment
  
Takeda unveiled data from the Phase III PhALLCON trial of Iclusig in an ASCO monthly plenary session • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D